A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest 1997;15(4):311-7
Date
01/01/1997Pubmed ID
9246151DOI
10.3109/07357909709039731Scopus ID
2-s2.0-0030797719 (requires institutional sign-in at Scopus site) 22 CitationsAbstract
The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administrated at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria. 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted.
Author List
Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WAAuthor
William See MD Emeritus Professor in the Urology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAged
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Creatinine
Deferoxamine
Drug Resistance, Neoplasm
Humans
Hydroxyproline
Infusions, Intravenous
Lung Neoplasms
Lymphatic Metastasis
Male
Methylhistidines
Middle Aged
Pelvis
Prostatic Neoplasms
